Physician profile
David Doman
NPI 1437350634
$4,178.82
in general payments reported to CMS, 2019-2025
10 companies · $1,686 in 2025
The $1,686 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,375 · 2020: $351 · 2021: $154 · 2022: $44.62 · 2023: $62.93 · 2024: $506 · 2025: $1,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,782 · Food and Beverage: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,782.18 |
| Food and Beverage | $472.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omnilife Science, INC | $1,488.35 | 2025 | |
| Encore Medical, Lp | $1,419.19 | 2019-2022 | |
| Stryker Corporation | $423.37 | 2020-2025 | Mako |
| Depuy Synthes Sales INC. | $415.33 | 2024 | Corail |
| Osteoremedies, LLC | $120.63 | 2019 | |
| Zimmer Biomet Holdings, INC. | $88.28 | 2019-2022 | |
| Medical Device Business Services, INC. | $75.00 | 2024 | Velys |
| Medacta USA, INC. | $68.52 | 2019 | |
| Team 1, LLC | $64.37 | 2025 | |
| Gilead Sciences, INC. | $15.78 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Doman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.